Tarceva® (erlotinib) tablets

A therapeutic advance in the treatment of 2nd line NSCLC and 1st line pancreatic cancer

Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Tarceva is also approved for the first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine (chemotherapy).

Learn more about Tarceva
Read full indication and safety information
See Tarceva Prescribing Information


Oncology

Because every day is precious for our patients

An important part of our mission is to improve upon the available treatment options for patients suffering from cancer with treatments such as our flagship product, Tarceva. OSI scientists are at the forefront of a paradigm-shifting movement toward molecular targeted and better tolerated therapies.

Access more information on our oncology programs



Diabetes & Obesity

Novel therapeutic approaches to tackling type 2 diabetes and obesity

We’re all about developing medicines that can improve the lives of patients and have potential drug candidates for type 2 diabetes and obesity, two areas with major unmet medical needs.

Access more information on our diabetes and obesity programs



* These websites are not endorsed by OSI, and OSI is not responsible for their content.


Helping patients learn about recent advances in cancer treatment and providing general information about cancer, types of treatments and resources available to patients and their families.

Visit targetedtherapy.info



Now enrolling patients in a Phase III clinical trial testing Tarceva as an adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer with EGFR-positive tumors.

Learn more about the RADIANT Study


OSI’s Oncology research team strives to be a world leader in the development of Molecular Targeted Therapies for the treatment of cancer through exploiting the science underpinning the Epithelial Mesenchymal Transition (EMT).

Learn more